Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.56 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17642069 | 1.00 | ACE (0.56) | ACETRHDEPPARAPPARGPPARD | |
| SCHEMBL19508750 | 0.92 | KLK5 (0.51) | ACETRHDEPPARAPPARGCTSS | |
| SCHEMBL5358340 | 0.90 | MAPT (0.46) | ACETRHDEPPARAPPARGCTSS | |
| SCHEMBL6324267 | 0.90 | ACE (0.52) | ACEPPARAPPARGPPARDCTSS | |
| SCHEMBL755381 | 0.89 | TRHDE (0.54) | ACETRHDECPB2 | |
| SCHEMBL29401545 | 0.88 | PPARA (0.56) | ACEPPARAPPARGCTSSCTSL | |
| SCHEMBL29401820 | 0.88 | PPARA (0.56) | ACEPPARAPPARGCTSSCTSL | |
| SCHEMBL30064788 | 0.87 | CTSS (0.47) | ACETRHDECTSSCTSLCTSB | |
| SCHEMBL8121406 | 0.85 | CTSS (0.52) | CTSSCTSLCTSBCTSKAKT1 | |
| SCHEMBL8121405 | 0.85 | CTSS (0.52) | CTSSCTSLCTSBCTSKAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | ACE 1072/4885TRHDE 1580/4885PPARA 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.